InsidersTradesSigma
申报总数
公司
▲ 买入（1 笔）
▼ 卖出（0 笔）
内部人交易记录
首席执行官已披露买入
1
已披露卖出
0
尚无足够的、已确定 T+90 期限的买入信号来衡量交易记录。
信号历史
Discover the complete record of transactions filed by Kathiresan Sekar, 首席执行官. Director active across 1 company, notably Verve Therapeutics, Inc.. Aggregated, 13 filings have been published. Split: 1 buy · 0 sell. Total volume traded: €40k. Activity tracked since 21 June 2021. The latest transaction was filed on 4 December 2024 (Don). Regulator: SEC (Form 4). The full history is accessible without signup.
Companies and markets linked to Kathiresan Sekar
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
申报13 总计
348,431 股Common StockSEC:0000950170-25-099260:0
33,000 股Common StockSEC:0000950170-25-050563:0
30,000 股0Common StockSEC:0000950170-24-133290:0
30,000 股@ US$2.8710.1% 占其流量Common StockSEC:0000950170-24-080012:0
50,000 股@ US$1.398.9% 占其流量Common StockSEC:0001209191-22-052799:0
50,000 股@ US$1.398.5% 占其流量Common StockSEC:0001209191-22-045447:0
50,000 股@ US$1.398.6% 占其流量Common StockSEC:0001209191-22-042871:0
160,000 股0Common StockSEC:0001209191-22-042265:0
69,674 股@ US$2.8728.6% 占其流量Common StockSEC:0000899243-22-011767:0
1,870 股@ US$1.390.4% 占其流量Common StockSEC:0000899243-22-001203:0
42,000 股@ US$1.398.2% 占其流量Common StockSEC:0000899243-21-050032:0
57,000 股@ US$1.3911.1% 占其流量Common StockSEC:0000899243-21-049812:0
2,500 股@ US$19.006.3% 占其流量Common StockSEC:0000899243-21-025070:0
标准退出：2021年9月19日 (T+90)
13 条申报中的 13 条
About Kathiresan Sekar
Kathiresan Sekar is Chief Executive Officer at Verve Therapeutics, Inc. (XNAS). He has filed 13 disclosures in total, and across the sampled recent filings dated from 2021-06-21 to 2025-07-28, buys amount to EUR 39874 with no sells; the most frequent transaction type is Levée d'options.
